VX11-770-108 Ivacaftor in 2-5 yr old CF Pts with CFTR Gating Mutation

• Research type

  Research Study

• Full title

  A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who are 2 Through 5 Years of Age and Have a CFTR Gating Mutation

• IRAS ID

  126577

• Contact name

  Jane Davies

• Contact email

  j.c.davies@imperial.ac.uk

• Sponsor organisation

  Vertex Pharmaceuticals Incorporated

• Eudract number

  2012-000204-15

• ISRCTN Number

  n/a

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  13/LO/0566

• Date of REC Opinion

  28 Jun 2013

• REC opinion

  Further Information Favourable Opinion